Stock Events

Stock Events

Oncotherpapy Science 

€0.1
13
+€0.01+6.74% Tuesday 06:02

Statistics

Day High
0.1
Day Low
0.1
52W High
0.19
52W Low
0.06
Volume
-
Avg. Volume
-
Mkt Cap
32.17M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.16
-0.88
-0.61
-0.33
Expected EPS
N/A
Actual EPS
N/A

Financials

-108.98%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
9.27MRevenue
-10.1MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 30O.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Eisai
4523.TSE
Mkt Cap1.69T
Eisai Co., Ltd. focuses on the discovery, development, and commercialization of oncology drugs, directly competing in the cancer treatment market.
Shionogi &.
4507.TSE
Mkt Cap2.12T
Shionogi & Co., Ltd. engages in the development of pharmaceutical products, including therapies for cancer, positioning it as a competitor in the oncology sector.
Chugai Pharmaceutical
4519.TSE
Mkt Cap6.03T
Chugai Pharmaceutical Co., Ltd. specializes in biopharmaceuticals, including cancer treatments, making it a direct competitor in the oncology field.
Daiichi Sankyo.
4568.TSE
Mkt Cap8.21T
Daiichi Sankyo Company, Limited focuses on the development of novel oncology therapies, competing in the same therapeutic area as Oncotherapy Science.
Kyowa Kirin.
4151.TSE
Mkt Cap1.75T
Kyowa Kirin Co., Ltd. works on innovative drug discovery in oncology among other areas, competing for market share in cancer treatment.
Astellas Pharma
4503.TSE
Mkt Cap3.68T
Astellas Pharma Inc. is involved in the development of new therapeutic drugs in oncology, making it a competitor in the cancer treatment market.
Sumitomo Pharma.
4506.TSE
Mkt Cap419.94B
Sumitomo Pharma Co., Ltd. has a focus on creating innovative therapies, including for cancer, positioning it as a competitor in the oncology space.
OtsukaLtd.
4578.TSE
Mkt Cap2.43T
Otsuka Holdings Co., Ltd. has a diversified portfolio that includes developing oncology treatments, making it a competitor in the cancer therapy market.
Fujifilm
4901.TSE
Mkt Cap2.83T
Fujifilm Holdings Corporation, through its bio-CDMO division, is expanding into healthcare, including cancer treatment, positioning it as a competitor.
Nano
4571.TSE
Mkt Cap14.49B
Nippon Shinyaku Co., Ltd. focuses on the research and development of pharmaceuticals, including cancer treatments, making it a competitor in the oncology market.

About

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
Show more...
CEO
Mr. Hatsuo Kato
Employees
47
Country
JP
ISIN
JP3202150003
WKN
000726692

Listings

TSE
JP
4564.TSE
F
DE
30O.F

0 Comments

Share your thoughts

FAQ

What is Oncotherpapy Science stock price today?▼
The current price of 30O.F is €0.1 EUR — it has increased by +6.74% in the past 24 hours. Watch Oncotherpapy Science stock price performance more closely on the chart.
What is Oncotherpapy Science stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncotherpapy Science stocks are traded under the ticker 30O.F.
Is Oncotherpapy Science stock price growing?▼
30O.F stock has risen by +0.53% compared to the previous week, the month change is a +11.76% rise, over the last year Oncotherpapy Science has showed a -22.76% decrease.
What is Oncotherpapy Science market cap?▼
Today Oncotherpapy Science has the market capitalization of 32.17M
When is the next Oncotherpapy Science earnings date?▼
Oncotherpapy Science is going to release the next earnings report on May 11, 2026.
What were Oncotherpapy Science earnings last quarter?▼
30O.F earnings for the last quarter are -0 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Oncotherpapy Science revenue for the last year?▼
Oncotherpapy Science revenue for the last year amounts to 9.27M EUR.
What is Oncotherpapy Science net income for the last year?▼
30O.F net income for the last year is -10.1M EUR.
How many employees does Oncotherpapy Science have?▼
As of April 05, 2026, the company has 47 employees.
In which sector is Oncotherpapy Science located?▼
Oncotherpapy Science operates in the Health Care sector.
When did Oncotherpapy Science complete a stock split?▼
The last stock split for Oncotherpapy Science was on September 26, 2013 with a ratio of 500:1.
Where is Oncotherpapy Science headquartered?▼
Oncotherpapy Science is headquartered in Kawasaki, JP.